TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02625428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optison

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Description: A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Description: A routine diagnostic and color-Doppler US. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through your blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A regular ultrasound uses sound waves to produce images, but can't show blood flow.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Description: Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound (CEUS)
Description: Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast medium to traditional medical sonography. Ultrasound contrast agents rely on the different ways in which sound waves are reflected from interfaces between substances. This may be the surface of a small air bubble or a more complex structure.
Study: NCT04423432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower Extremity Resistance Exercise Training
Description: 3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Resistance Exercise Training
Description: 3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Extremity Resistance Exercise Training
Description: 3 times supervised exercise for 4 weeks Warm up (Self Paced walking for 10 minutes) leg press (8-12 RM) leg extension (8-12 RM) Sit to stand squat (with weight) Stationary Cycling (Maximum Resistance as per patient tolerance till failure)
Study: NCT00508365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol CR capsules
Description: The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol CR capsules
Description: The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules to match each dose level will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules to match each dose level will be provided.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril will be available as 10 milligrams tablets administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril will be available as 10 milligrams tablets administered orally once daily.
Study: NCT02846714

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FLARE
Study: NCT02467075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iopamidol 300 (Contrast)
Description: Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
Study: NCT03842514

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soya lecithin
Description: The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soya lecithin
Description: The lecithin supplement will be soya lecithin granules given as 7.5 g twice daily, incorporated into juices
Study: NCT03685123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity recommendations
Description: Participants in the PA-REC group will exercise at 550 MET min. per week in a supervised format

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight maintenance recommendations
Description: Participants in the WM-REC group will exercise at 970 MET min. per week in a supervised format

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIFAST weight loss
Description: Participants will participant in an OPTIFAST medical weight loss program and exercise training
Study: NCT04397601

Intervention type: DRUG
Intervention: Folfiri/Bevacizumab
Description: Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with bevacizumab (5 mg/kg) on day 1 of each 14-day cycle.

Intervention type: DRUG
Intervention: Folfiri/Aflibercept
Description: Irinotecan (180 mg/m2), leucovorin (400 mg/m2), fluorouracil as an intravenous bolus of 400 mg/m2, and fluorouracil as a continuous 46-h infusion of 2400 mg/m2 in combination with aflibercept (4 mg/kg) on day 1 of each 14-day cycle.
Study: NCT03974243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiauranib
Description: In the lead-in period, patients take 50mg Chiauranib capsules on the forth day .~In the subsequent treatment cycles, Chiauranib capsules are given orally once daily, 28 days as a cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8,11,15,18,22 and 25 of each cycle. 28 days as a cycle
Study: NCT03419325

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 test
Description: Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CYP2C19 test
Description: Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P2RY12 assay
Description: Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P2RY12 assay
Description: Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P2RY12 assay
Description: Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: P2RY12 assay
Description: Patients will be categorized into 4 groups based on the results of their genetic test for CYP2C19 as well as the residual platelet reactivity test (P2RY12 assay=PRU units) and DAPT treatments options will be recommended accordingly (i.e., through a Clinical Decision Support (CDS) tool that is based on a pharmacogenetic-driven algorithm and the PRU result).
Study: NCT01979354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spinal morphine
Description: 0.15 mg spinal morphine
Study: NCT02754479

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Description: Treatment of lower extremity spider veins
Study: NCT03319706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Torrent's Olmesartan Medoxomil Tablets 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daiichi Sankyo Inc's Benicar Tablets 40 mg
Study: NCT02666742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOAC
Description: DOAC is a blood thinning drug, also called direct oral anticoagulant. These group of drugs are approved by the U.S. Food and Drug Administration (FDA) for the treatment of stroke prophylaxis in atrial fibrillation and deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
Study: NCT02336776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.~Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session.
Study: NCT04028336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TITRATION
Description: PEP titration pulmonary opening (PEP-OP) was performed in all patients followed by new LUS and Peso measurement.
Study: NCT01199705

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous (Human) (SCIG)
Description: IgPro20 is a 20% (weight per volume \[w/v\]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
Study: NCT03026036

Intervention type: RADIATION
Intervention: PET Scan with Raclopride
Description: A subsample (21 per group) will complete the PET imaging.

Intervention type: RADIATION
Intervention: PET Scan with Raclopride
Description: A subsample (21 per group) will complete the PET imaging.

Intervention type: RADIATION
Intervention: PET Scan with Raclopride
Description: A subsample (21 per group) will complete the PET imaging.
Study: NCT02779517

Intervention type: OTHER
Intervention: Mobile Service Robot Survey
Description: The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).

Intervention type: OTHER
Intervention: Mobile Service Robot Survey for Patients
Description: The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact). This survey differs in terms of design questions.
Study: NCT03824080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Description: Bemcentinib will be self-administered orally (fasted) at a dose mentioned above for a total of at least 4 cycles daily.~Responding patients (defined as at least stable disease) are eligible for up to 5 additional cycles according to the maintenance daily dosing of 2 x 1 capsules of 100 mg for each 28 days cycle (up to 9 cycles in total).
Study: NCT01441934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil citrate
Description: sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pills
Description: placebo t.i.d.
Study: NCT01018212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cicatrix cream
Description: We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.~The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application.
Study: NCT01634334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-Time Intervention
Description: Lights and Sound Brief Coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Education
Description: Participants will receive usual education about secondhand smoke and thirdhand smoke.
Study: NCT01822795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung volume reduction coïl treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regular medical treatment

Intervention type: OTHER
Group type: OTHER
Intervention: Regular medical treatment
Study: NCT00515411

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Leucovorin, Fluorouracil, Cisplatin
Description: Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen
Description: Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg\* subcut x 7 d 10-17~\* 300 mcg for weight \< 60 kg, 480 mcg for weight \> 60 kg~Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab
Description: Treatment for Her2 Positive Participants~Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 mg/m2/d daily x 2 days Cisplatin 40 Day 2 OR 3 IVPB (30 min) Trastuzumab Administered on an every 2 week dosing schedule. Initial loading dose of 6 mg/kg over 90 minutes, followed by trastuzumab 4 mg/kg every 2 weeks over 30 minutes.
Study: NCT04423432

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Exercise Plan
Description: 2 sets of 10 repetitions/day of~1. AROM isolated knee extension and knee flexion~2. Isometric isolated knee extension and knee flexion~3. Isometric terminal knee extension~4. Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)
Study: NCT04600050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care and exercise education
Description: Provide exercise training materials after the education of exercise and health to enable home-based exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: Under the face-to-face supervisor, the eccentric exercise using a flywheel, and the self-directed home-based eccentric overload exercise using an elastic band are performed.
Study: NCT01640925

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine gluconate
Description: Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
Study: NCT04423432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Plan
Description: 2 sets of 10 repetitions/day of~1. AROM isolated knee extension and knee flexion~2. Isometric isolated knee extension and knee flexion~3. Isometric terminal knee extension~4. Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)
Study: NCT02204956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustained Care
Description: The Sustained Care intervention includes four main components: 1. a 40-minute individual session about quitting smoking during the hospital stay; 2. a 90-day telephone-based and text messaging program that provides support regarding smoking and nicotine patch use; 3. the opportunity, during the automated calls and texts to be transferred to quit smoking resources, including live telephone quit coaching counseling, web and text-based quit coaching resources; and 4. an 8-week supply of nicotine patches, provided at no cost.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care includes a brief, 5 - 10 minute education session about quitting smoking, delivered by a hospital nurse during the hospital stay. Written handouts to reinforce the educational session will also be provided.
Study: NCT04042896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exergame
Description: Exergame is 'exercise + game'.
Study: NCT01640925

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard bathing
Description: The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
Study: NCT03798444

Intervention type: RADIATION
Intervention: dual energy X-ray absorptiometry
Description: BMD of the lumbar spine, left femoral neck, and total hip were measured using dual energy X-ray absorptiometry. The lumbar spine, left femoral neck, or total hip of T-score ≤-2.5 as the osteoporosis

Intervention type: RADIATION
Intervention: lateral spine imaging from T4 to L4 on X-ray
Description: VFs were assessed using lateral spine imaging from T4 to L4 on X-ray .A visual semi-quantitative method was used, with fractures defined as a vertebral Vertebral fractures should be diagnose if height ratio \<0.80 for the anterior/posterior or middle/posterior height ratio within a vertebra, or the posterior/posterior height ratio when compared to an adjacent vertebra
Study: NCT01569425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: High Calorie breakfast and high calorie dinner

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: High Calorie breakfast and high calorie dinner
Study: NCT01173796

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: perimitral flutter ablation by blocking the mitral isthmus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: catheter ablation
Description: cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
Study: NCT04636008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab+Hypofractionated radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Hypofractionated Radiotherapy
Study: NCT03918603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ventral décubitus
Description: Patient will have one session at least more than 12 hours between inclusion and H48 of ventral décubitus
Study: NCT02794051

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Therapy
Description: Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
Study: NCT04043182

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrassound
Description: The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrassound
Description: The treatment protocol will consist of 10 sessions, lasting 20 minutes. The energy level corresponding to 59 J / cm2 (177 J / cm2) and frequency of 3 MHZ, applied in the anterior region of the abdomen, in a quadrant previously delimited with a ballpoint pen, will be used. The flanks (lateral of the abdomen) will not be treated.
Study: NCT00882102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 20 mg/m\^2 IV over 1-1/2 hours daily for 5 days.
Study: NCT03589131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conversion rate to open surgery
Description: In this interversion investigators try to measure how much is this arm feasible to completely perform the procedure whether robotically or laparoscopically without conversion to open surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Baseline demographics
Description: These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups
Study: NCT00882102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin
Description: Gemtuzumab ozogamicin 3 mg/m\^2 IV on day 5.